Fast Five Quiz: Type 2 Diabetes and Obesity and Weight Management

Anne L. Peters, MD

Disclosures

May 16, 2022

When glycemic control is not achieved with a single glucose-lowering agent, an additional medication can be added, but impact of weight should be considered when choosing the most appropriate glucose-lowering therapies. Studies have demonstrated that in addition to improving glucose and providing primary prevention for CVD, weight loss was consistently observed in patients taking GLP-1 RAs.

While GLP-1 RAs and SGLT2 inhibitors both promote weight loss, GLP-1 RAs are recommended in patients with obesity and overweight with weight-related comorbidities, and even in people without type 2 diabetes. GLP-1 RAs are an effective weight loss medication in many settings, with a greater reduction than is seen with SGLT2 inhibitors. This class is considered to have a high efficacy with regard to A1C reduction, making it an alternative to insulin in some cases.

SGLT2 inhibitors are recommended in patients with established CVD and have shown significant benefit in patients with type 2 diabetes and HF, CVD, and/or CKD. This class of agents has been shown to have an intermediate efficacy with regard to A1C lowering. It does not cause hypoglycemia.

Learn more about type 2 diabetes.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....